Logo

GNPX

Genprex, Inc.

GNPX

Genprex, Inc. • NASDAQ
$2.96 ▲ 2.07% (+0.06)
Market Cap $4.83 M
52w High $63.00
52w Low $2.77
Dividend Yield 0%
P/E 0
Volume 55.99K
Outstanding Shares 1.63M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $3.346M ▼ $-3.799M ▲ 0% $-5 ▲ $-3.799M ▲
Q2-2025 $0 $4.682M ▲ $-4.675M ▼ 0% $-8.5 ▲ $-4.682M ▼
Q1-2025 $0 $3.969M ▼ $-3.965M ▲ 0% $-13 ▲ $-3.968M ▲
Q4-2024 $0 $4.335M ▲ $-4.33M ▼ 0% $-21 ▲ $-4.33M ▼
Q3-2024 $0 $4.322M $-4.316M 0% $-61.5 $-4.315M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.103M ▼ $3.563M ▼ $2.795M ▲ $767.807K ▼
Q2-2025 $1.347M ▼ $3.828M ▼ $2.436M ▲ $1.391M ▼
Q1-2025 $3.468M ▲ $6.01M ▲ $2.142M ▼ $3.868M ▲
Q4-2024 $1.602M ▲ $4.124M ▲ $2.504M ▲ $1.62M ▼
Q3-2024 $1.488M $3.907M $2.242M $1.665M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.799M ▲ $-3.187M ▲ $0 $2.944M ▲ $-243.529K ▲ $-3.187M ▲
Q2-2025 $-4.675M ▼ $-3.864M ▲ $0 $1.743M ▼ $-2.121M ▼ $-3.864M ▲
Q1-2025 $-3.965M ▲ $-4.161M ▼ $0 $6.028M ▲ $1.867M ▲ $-4.161M ▼
Q4-2024 $-4.33M ▼ $-3.869M ▼ $0 ▲ $3.983M ▲ $113.379K ▲ $-3.869M ▼
Q3-2024 $-4.316M $-1.412M $-773.478K $1.215M $-970.743K $-1.412M

Five-Year Company Overview

Income Statement

Income Statement Genprex is still a pure research and development company, with no commercial revenue yet. All of its spending flows straight to the bottom line as operating losses, which is normal for an early-stage biotech but still important to recognize. Losses have been steady for several years and then appear to spike sharply in the most recent period, likely reflecting accounting impacts and the cost of advancing trials and corporate actions. Earnings per share figures look extreme, largely because of reverse stock splits and a small share base, so the headline numbers can appear more dramatic than the underlying cash burn would suggest. Overall, this is a classic pre-revenue biotech profile: costs today in pursuit of potential future products, with no offsetting sales yet.

Balance Sheet

Balance Sheet The balance sheet is very light and dominated by cash, with only a small amount of total assets and equity and effectively no financial debt. That means Genprex is not burdened by interest payments, but it also does not have a deep cushion of resources. Its financial flexibility rests mainly on its ability to raise new capital rather than on a large asset base. The recent pattern of sizable reverse stock splits signals that the company has likely issued a lot of shares over time to fund operations and may have been working to maintain listing requirements. In simple terms, the balance sheet is clean but thin, which makes ongoing access to funding particularly important.

Cash Flow

Cash Flow Cash flows show a consistent pattern of money going out to fund research, clinical trials, and overhead, with no operating cash coming in from product sales. Capital spending is minimal, so almost all cash burn is tied to people, trials, and development rather than heavy equipment or facilities. Free cash flow is therefore negative year after year, which is typical for a small clinical-stage biotech but means the company must periodically raise fresh funds to keep its programs moving. The key question is not just how much cash goes out each year, but how effectively that spending is converted into clinical progress and value-creating milestones.

Competitive Edge

Competitive Edge Genprex sits in a specialized niche within oncology and metabolic disease, focusing on gene therapies rather than traditional drugs. Its main differentiator is a proprietary non-viral delivery platform designed to target tumors more selectively and to allow repeat dosing with fewer immune issues. This creates a distinct position versus many peers that depend on viral vectors or entirely different technologies. The company has attracted regulatory attention with fast track and orphan drug designations, which can shorten timelines and support its credibility. At the same time, it operates in a highly competitive space with large, well-funded pharma and biotech companies working on lung cancer and diabetes treatments using multiple approaches. As a smaller player, Genprex’s competitive strength will depend heavily on the quality of its clinical data, its ability to form partnerships, and how well it can protect and extend its intellectual property.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Genprex’s story. Its Oncoprex platform is a versatile gene delivery technology designed to carry tumor suppressor genes directly into cancer cells, and its lead candidate, REQORSA, builds on that to tackle difficult forms of lung cancer, including patients who have failed existing targeted therapies or immunotherapies. Early trial results highlight a tolerable safety profile with hints of clinical activity, which is encouraging at this stage. Beyond cancer, the GPX-002 program takes a different, virus-based approach aimed at reprogramming pancreatic cells to restore insulin production, a potentially transformative idea for both Type 1 and Type 2 diabetes. The decision to spin off the diabetes assets suggests management wants to give that program dedicated focus and possibly attract specialized investors or partners. A growing patent estate, including protection on key combinations and uses well into the next decade, underpins the R&D story and helps support a potential moat if the science translates into successful products.

Summary

Genprex is a classic early-stage biotech: science-rich, revenue-poor, and financially dependent on external capital. The company’s financial statements show no commercial sales, ongoing operating losses, modest but clean assets centered on cash, and a steady outflow of funds to support research and clinical work. Reverse stock splits and a thin equity base highlight a history of dilution and the ongoing need to fund operations. On the upside, Genprex has carved out a distinctive technological angle with its gene delivery platform and lead programs in lung cancer and diabetes, supported by patents and favorable regulatory designations. On the downside, it faces intense competition, scientific and regulatory risk inherent in gene therapy, and a narrow financial cushion. The overall picture is one of a high-risk, high-uncertainty development-stage company whose future will hinge on clinical data, partnership activity, and its ability to secure sustainable funding while advancing its pipeline.

NEWS

November 24, 2025 · 7:00 AM UTC

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Read more

November 19, 2025 · 7:00 AM UTC

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Read more

November 18, 2025 · 7:00 AM UTC

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Read more

November 4, 2025 · 7:00 AM UTC

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Read more

October 28, 2025 · 11:19 AM UTC

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Read more